Investor Relations

Sophiris Bio Inc. is a late-stage, clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.

NASDAQ | SPHS $2.28 0.00 (0.000%)
High N/A
Low N/A
Volume N/A
Market Cap 68.65M

10/17/17 4:00 PM ET

Pricing provided by eSignal
Delayed 20 minutes